A regulatory shorthand with real technical consequences GxP stands for “Good x Practice,” where x represents any of the regulated pharmaceutical domains: manufacturing (GMP), laboratory (GLP), clinical (GCP), distribution (GDP), and pharmacovigilance (GVP). The term is a collective reference to the quality management frameworks that govern how pharmaceutical products are developed, manufactured, tested, stored, distributed, and monitored after market release. The acronym appears everywhere in pharma compliance discussions, but its simplicity is misleading. Each GxP domain carries distinct regulatory requirements, different enforcement mechanisms, and different implications for software systems. A system that is compliant with GLP requirements is not automatically GMP-compliant — the domains overlap in principles but diverge in specifics. For engineering teams, this is the practical consequence: scoping work to “make it GxP” without naming the domain is the first step toward over-validating non-critical paths and under-validating critical ones. The GxP domains mapped GxP Full name What it governs Key software implication GMP Good Manufacturing Practice Production, packaging, labelling, storage Batch records, process control, environmental monitoring GLP Good Laboratory Practice Non-clinical safety studies Study data, sample tracking, instrument qualification GCP Good Clinical Practice Clinical trials, human subject data Randomisation, data capture, adverse event reporting GDP Good Distribution Practice Storage and transport of finished products Temperature monitoring, chain-of-custody, serialisation GVP Good Pharmacovigilance Practice Post-market safety surveillance Signal detection, case processing, periodic safety reports Software systems intersect with GxP when they create, modify, store, or transmit data relevant to any of these domains. A laboratory information management system (LIMS) falls under GLP when supporting non-clinical studies and under GMP when supporting release testing. The same system may carry different GxP obligations depending on the data it processes — and a single PostgreSQL instance backing both flows inherits the stricter regime for each table it owns. Why engineering teams need to understand GxP scope In our experience, the most common mistake engineering teams make with GxP is treating it as a binary property of systems rather than a property of the data and processes those systems support. A database server hosting both GMP batch records and non-GxP administrative data is not entirely GxP-relevant — but the GMP data it stores carries GxP obligations regardless of the system architecture. The boundary runs through the schema, not around the server. This distinction matters for AI system deployment. A machine learning model that analyses pharmaceutical manufacturing data to suggest process optimisations is GxP-relevant if its suggestions influence quality-affecting decisions. The same model architecture — same PyTorch checkpoint, same ONNX export, same inference container — deployed for non-GxP applications (facility energy management, workforce scheduling) carries no GxP obligations. The model weights do not change; the regulatory weight attached to their outputs does. We work through this scoping question explicitly at project kickoff, because the cost of getting it wrong runs in both directions. Over-scoping pulls auxiliary systems into validation programmes they do not need, slowing delivery for no compliance benefit. Under-scoping leaves quality-affecting outputs unvalidated and surfaces as an inspection finding months later. The full compliance requirements for AI software under GxP depend on which specific GxP domain applies, what data the system processes, and whether the system’s outputs affect product quality or patient safety. GxP is not a certification There is no GxP certificate that a company or system can obtain. GxP compliance is a demonstrable state — maintained through validated processes, controlled documentation, qualified personnel, and ongoing quality oversight. Regulatory inspectors assess compliance by examining evidence: validation documentation, audit trails, change control records, training records, and deviation investigations. A company claims GxP compliance for specific processes and systems, not for the organisation as a whole. An FDA inspector examining a manufacturing facility evaluates cGMP compliance for the specific products, processes, and systems within the inspection scope. A finding of non-compliance in one area does not invalidate compliance in unrelated areas — but it does trigger regulatory scrutiny that often expands the inspection scope, which is why isolated remediation is rarely as cheap as it first looks. How do GxP requirements shape software architecture? Engineering teams building software for pharmaceutical environments need GxP understanding not because they own regulatory compliance — that is Quality Assurance’s role — but because GxP requirements fundamentally shape software architecture, development processes, and deployment practices. The decisions land in code long before they land on a validation report. Audit trail requirements (every data change must be logged with who, what, when, and why) affect database design, API design, and user interface design from the architectural level. Retrofitting audit trails into a system designed without them requires touching every data modification path — often a near-complete rewrite. The pattern we see most often: a team adds a last_modified_by column late in the project and discovers that half their write paths bypass the application layer entirely. Electronic signature requirements (21 CFR Part 11) dictate authentication architecture, session management, and signing workflow design. A system where users “sign” by clicking an OK button without password re-entry does not meet regulatory requirements and will be flagged during inspection. The signing event must be cryptographically bound to the user, the record, the timestamp, and the meaning of the signature — four bindings, not one. Change control requirements mean that every software update — including bug fixes, configuration changes, and dependency updates — must be assessed for GxP impact, documented, tested, and approved before deployment. This fundamentally changes the deployment cadence: regulated systems cannot adopt continuous deployment practices without a compliant change control wrapper. Teams that try to keep a daily release rhythm typically end up with a parallel “non-GxP track” for cosmetic changes and a slower track for anything that touches validated functionality, with explicit gating between them in their CI pipeline. We train engineering teams on these requirements at project kickoff because discovering them mid-development forces expensive rearchitecting. A focused workshop covering audit trails, electronic signatures, data integrity requirements, and change control procedures saves weeks of rework later in the project. ALCOA+ as the architectural thread Data integrity — the ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available) — is the thread connecting all GxP requirements for software systems. Every architectural decision should be evaluated against these principles: Attributable — does the system record who created or modified data, including service accounts running automated jobs? Legible — is data stored in formats that remain human-readable and machine-readable across the retention period (often 10+ years)? Contemporaneous — are timestamps generated automatically by the system at the moment of the event, rather than entered manually after the fact? Original — can the original record be distinguished from copies, exports, and derived analyses? Accurate — are there controls preventing unauthorised modification, and is the modification path itself audited? These principles, rather than the specific regulation text, are the practical guide for engineering teams designing GxP-compliant systems. A team that internalises ALCOA+ early will make the right architectural choices without needing to re-read 21 CFR Part 11 every sprint. FAQ What does GxP compliance specifically require when the software is AI/ML rather than deterministic code? The core GxP obligations — audit trail, electronic signatures, change control, data integrity — still apply, but two AI-specific concerns are layered on top: model lifecycle management (training data lineage, model versioning, retraining triggers) and inference traceability (which model version produced which output for which input). Deterministic code is validated once per release; an AI system is validated against a frozen model, and any model change is a change-control event. Which GxP rules apply to AI training data, models, and inference outputs? Training data inherits the GxP status of its source: data drawn from GMP batch records is GMP-relevant and must satisfy ALCOA+ in its training pipeline. Models that influence quality-affecting decisions are themselves GxP-relevant artifacts subject to versioning, change control, and validation evidence. Inference outputs that feed into release decisions, deviation investigations, or regulatory submissions must be auditable end-to-end — input, model version, output, and reviewer all linked. How is a GxP-validated AI system kept compliant as the model retrains or drifts? Through a documented model lifecycle that treats retraining as a controlled change. Each retraining event is preceded by a change assessment (does the new training data shift the model’s risk profile?), accompanied by performance validation against a held-out qualification set, and concluded with QA approval before deployment. Drift monitoring runs continuously, and a drift threshold breach triggers the change control process — it is not handled silently in production. Where is the boundary between GxP and non-GxP usage of AI inside a pharma manufacturing workflow? The boundary follows the data and the decision, not the system. An AI model that suggests process parameter adjustments to operators on the shop floor is GxP-relevant because its output influences a quality-affecting action. The same model architecture deployed to forecast utility consumption is not GxP-relevant. When a single deployment serves both purposes, the GxP regime applies to the GxP-relevant path end-to-end. Which GxP roles (system owner, QA, validation lead) own AI-specific risks and how is that documented? The system owner remains accountable for fitness-for-purpose and is the named owner of the AI system in the validation master plan. QA owns the compliance assessment and approves the validation strategy. A validation lead executes the protocol. AI-specific risks — training data drift, model degradation, explainability gaps — are typically documented in the system’s risk assessment with named owners for each mitigation, and reviewed at a defined cadence rather than only at release. How do ISPE’s GAMP AI guidance and the ISPE AI maturity model fit into an existing GxP programme? GAMP 5 (Second Edition) and the ISPE GAMP AI guidance extend the existing GAMP category framework to AI/ML systems, giving teams a structured way to classify AI software and scale validation effort to risk. The ISPE AI maturity model is an organisational self-assessment tool — useful for identifying capability gaps in governance, data management, and lifecycle controls, but not a replacement for system-level validation. Most teams use the maturity model to plan their programme and GAMP guidance to execute individual system validations within it.
